Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...

Serotonin can promote both pulmonary vasoconstriction and pulmonary vascular remodeling and is thought to be involved in the pathobiology of PAH. A polymorphism in the serotonin transporter (SERT ...

Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy ...

Right ventricular hypertrophy, right ventricular systolic pressure, and vascular remodeling—all complications of pulmonary hypertension—were reduced as compared with controls that did not ...

cholesterol the role of natriuretic peptide signaling and mineralocorticoid receptor antagonism in protecting against adverse remodeling in the pressure-overloaded heart the molecular pathogenesis of ...

Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merck’s sotatercept. Backed by $97.5M, results will ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

In PAH, these remodeling processes within these arterioles ... exercise tolerance and pulmonary vascular resistance. Due to this superiority, the study was terminated prematurely—a continuation ...

cholesterol the role of natriuretic peptide signaling and mineralocorticoid receptor antagonism in protecting against adverse remodeling in the pressure-overloaded heart the molecular pathogenesis of ...